WO2004094393A1 - Phospholipase inhibitors - Google Patents

Phospholipase inhibitors Download PDF

Info

Publication number
WO2004094393A1
WO2004094393A1 PCT/US2004/006095 US2004006095W WO2004094393A1 WO 2004094393 A1 WO2004094393 A1 WO 2004094393A1 US 2004006095 W US2004006095 W US 2004006095W WO 2004094393 A1 WO2004094393 A1 WO 2004094393A1
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
oxo
isoxazole
alkyl
benzylamide
Prior art date
Application number
PCT/US2004/006095
Other languages
French (fr)
Inventor
Patrick Irving Eacho
Patricia Sue Foxworthy-Mason
Ho-Shen Lin
Jose Eduardo Lopez
Marian Kazimierz Mosior
Michael Enrico Richett
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Priority to EP04723449A priority Critical patent/EP1613608A1/en
Priority to US10/544,908 priority patent/US7217727B2/en
Publication of WO2004094393A1 publication Critical patent/WO2004094393A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Definitions

  • This invention relates to novel 3-oxo-3H-benzo[ ⁇ T]isoxazole carboxamide compounds useful for the treatment and/or prevention of diseases mediated by phospholipases including hepatic and endothelial lipase.
  • Hepatic lipase plays an important role in lipid metabolism.
  • Hepatic lipase is a glycoprotein that functions as a ligand or as an enzyme of approximately 65Kda, which has been shown to catalyze the hydrolysis of lipids including triglycerides, diglycerides and phospholipids in native lipoproteins. It has also been shown to. facilitate the selective uptake of cholesterol from high-density lipoproteins and the removal of remnant particles by the liver (Jonathan C. Cohen, et al Biochemistiy 1992, 31: 8544-8551 and Neve et al Biochemistry J. 1998, 330:701-706).
  • the inverse relationship between hepatic lipase activity and the level of HDL- cholesterol, particularly type-2 HDL-cholesterol, can be used to advantage in up- regulating the Level of HDL cholesterol-the good cholesterol.
  • Endothelial lipase is a newly described member of the lipase gene family. Like hepatic lipase, endothelial lipase has been implicated in the hydrolysis of HDL phospholipids and in the reduction of HDL-cholesterol in vivo. In experiments using hepatic lipase knockout mice the infusion of a polyclonal antibody inhibitory to endothelial lipase resulted in a marked increase in HDL- cholesterol levels (Rader, D. J., et al Journal of Clinical Investigation (2003), 111(3) 357-362.
  • the present invention provides a 3-oxo-3H-benzo[fi ]isoxazole carboxamide compound of formula (I):
  • R] is selected from the group consisting of hydrogen, C ] -C 13 alkyl, C j - C 20 haloalkyl, C 2 -C ]3 alkenyl, C 2 -C 20 alkynyl, C j -C j j alkoxyalkyl, C ] -C ]3 alkylamine, C ⁇ - C 5 alkylcycloalkyl, Cj-Csalkylcycloalkenyl, cycloalkyl, cycloalkenyl, C j -C 5 alkylaryl, C(O)C -C.alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from d-C 6 alkyl, halo, haloalkyl, COOH,
  • the present invention provides the use of a 3-oxo-3H-benzo[ ⁇ i]isoxazole carboxamide compound of formula (I):
  • R] is selected from the group consisting of hydrogen, C j -C ]3 alkyl, C ⁇ - C 20 haloalkyl, C 2 -C 13 alkenyl, C 2 -C 20 alkynyl, C ] -C ]3 alkoxyalkyl, C r C ] 3 alkylamine, C ⁇ - C 5 alkylcycloalkyl, C]-C alkylcycloalkenyl, cycloalkyl, cycloalkenyl, C ] -C 5 alkylaryl, C(O)C j -C 6 alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from C]-C 6 alkyl, halo, haloalkyl, COOH, C(
  • R 2 is hydrogen
  • R3, R4 R5, and R5, are each independently selected from hydrogen, halo, hydroxy, amino, C 2 -C ]2 alkyl, C ⁇ -C ]2 haloalkyl, C 2 -C 12 alkenyl, C 2 -C ]2 alkynyl, C 2 - C ]2 alkylaryl, C j -C ⁇ alkylcycloalkyl, C r C ]2 alkylcycloalkenyl, COOH, C(O)C f C 6 alkyl, C(O)OC r C 6 alkyl, C(O)NR a R b , C r C ]2 alkylheterocyclic, phenyl, or aryl; wherein R a and R b are independently selected from C ] -C 5 alkyl, C 2 -C 5 alkenyl, phenyl, benzyl, and C ] -C 5 alkylcycloalkyl; or a
  • the present invention provides the use of 3-oxo-3H-benzo
  • the present invention also relates to the use of compounds of formula I useful in the treatment and/or prevention of hepatic lipase and/or endothelial lipase mediated diseases, comprising administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate to a patient in need thereof.
  • the present invention also relates to the use of a novel 3-oxo-3H- benzo[ ⁇ i]isoxazole carboxamide compound of formula I to increase or mediate the increase of high-density lipoproteins (HDL) upon administration to a patient in need thereof.
  • HDL high-density lipoproteins
  • the present invention provides a pharmaceutical composition containing any of the compounds of the invention.
  • the present invention also relates to the use of a pharmaceutical formulation comprising a compound of formula I and a carrier and/or diluent for the treatment and/or prevention of hypercholesterolemia.
  • the present invention relates to the use of a compound of fomiula I for the manufacture of a medicament for the treatment and/or prevention of hepatic lipase and/or endothelial lipase-mediated diseases comprising administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate to a patient in need thereof.
  • mammal and mammalian include human and domesticated quadrupeds.
  • hepatic lipase and/or endothelial lipase mediated-diseases refers to diseases symptomatic of low HDL levels, caused by, modulated by, exacerbated by or induced directly or indirectly by elevated hepatic lipase and/or endothelial lipase activity, and include for example, hypercholesterolemia, hyperlipidemia, stroke, hypertriglyceridemia, atherosclerosis and related diseases.
  • Treatment and/or prevention of such diseases comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula I in an amount sufficient to inhibit, ameliorate and/or prevent hepatic lipase and/or endothelial lipase activity and to thereby inhibit or prevent the deleterious effects of hepatic lipase and/or endothelial lipase activity.
  • Active Ingredient refers to a compound(s) of Formula (I) or a pharmaceutically acceptable salt, solvate, prodrug, racemate or enantiomer thereof either as the pure compound or delivered as a pharmaceutical formulation or a pha ⁇ naceutical composition.
  • the pharmaceutical composition or formulation containing a compound of the invention and other compound(s) or treatment regimens useful for the treatment and/or prevention of diseases associated with or exacerbated by hepatic lipase and/or endothelial lipase activity (combination drugs) are contemplated to be within the meaning of the term "Active Ingredient(s)."
  • alkyl by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical, such as for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n- pentyl, and n-hexyl.
  • alkenyl employed alone or in combination with other terms means a straight chain or branched monovalent hydrocarbon group having the stated number ranges of carbon atoms, and typified by groups such as vinyl, propenyl, crotonyl, isopentenyl, and various butenyl isomers.
  • hydrocarbyl means an organic group containing only carbon and hydrogen.
  • Carboxy means an organic group containing only carbon and oxygen, i.e.the group -C(O)-.
  • halo means fluoro, chloro, bromo, or iodo.
  • heterocyclic radical or “heterocyclic group” refers to radicals or groups derived from monocyclic or polycyclic, saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5 to 14 ring atoms and containing from 1 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur.
  • Typical heterocyclic radicals are pyrrolyl, pyrrolodinyl, piperidinyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, benzo(b)thiophenyl, carbazolyl, norharmanyl, azabenzo(b)thiophenyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, indazolyl, imidazo(1.2-A)pyridinyl, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl, benzothiazolyl, purinyl, pyridinyl, dipyridylyl.
  • C2 ⁇ )alkylheterocyclic represent respectively a (Cj-Ci 2)alkyl, (C ⁇ -Ci2)alkyl, or (Cj- C ⁇ alkyl group attached to a cylopentyl, cyclohexyl, and heterocyclic group wherein the entire group is attached to the 3-oxo-3H-benzo[ ⁇ ']isoxazole nucleus (X) at the alkyl terminus.
  • the pattern as above is reflective of the naming system or connotation employed herein.
  • C]-C) alkylcycloalkyl means the C ⁇ -C 12 alkyl group is substituted on the cycloalkyl group and the composite group is attached to the nucleus at the alkyl terminus.
  • cycloalkyl or "(C -C 8 )cycloalkyl” without more implies a cycloalkyl group having from 3 to 8 carbon atoms.
  • substituted group is an organic group substituted with one or more "non-interfering" substituents.
  • non-interfering is meant that the group is suitable chemically and stability-wise to occupy the designated position and perform the designated or intended role. Thus unsuitable groups are excluded from the definition of "non-interfering”.
  • group As used herein the terms "group”, “radical” or “fragment” are synonymous and are intended to indicate functional groups or fragments of molecules attachable to a bond or other fragments of molecules.
  • acetamide group represent the acetamide fragment or radical. Structures of groups, radicals or fragments unattached to the 3-oxo-3H-benzo[ ⁇ )isoxazole nucleus have been drawn to show the first line as a connecting bond only.
  • alkylene chain of 1 or 2 carbon atoms refers to the divalent radicals, CH2-CH2- and -CH2-.
  • the present invention provides the use of a novel class of 3-oxo-3H- benzo[ ⁇ ?]isoxazole compounds useful as inhibitors of hepatic lipase and/or endothelial lipase activity for the treatment, amelioration and/or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.
  • the compounds of the invention are represented by the general formula (I) and include pharmaceutically acceptable salts, or enantiomers, prodrugs or solvates thereof.
  • the preferred group for R ⁇ is a substituted or unsubstituted group selected from the group consisting of C 2 -C 13 alkyl, C -C ]3 alkenyl, C -C ⁇ oalkoxyalkyl, C 5 -C] cycloalkenyl, cycohexylmethyl, cyclopentylmethyl, cyclohexylethyl, phenyl, naphthyl, toluyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenyl and cyclohexenyl.
  • R 1 is a benzyl group substituted with one, two or three groups independently selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl, methylcyclopentyl, cylopentyl, cyclohexyl, methycyclohexyl, cyclohexylmethyl, cycloheptylmethyl, phenyl and benzyl.
  • R ⁇ group is a benzyl group substituted with one, two or three groups independently selected from methyl, ethyl, isopropyl, isobutyl, tert-butyl.
  • R 3 , R4, R 5 , and R 6 are preferably selected independently from the group consisting of hydrogen, halo, hydroxy, amino, C ⁇ -C4alkyl, C2-C4alkenyl, -CO-(C ⁇ - C4)alkyl,-COOH, -COO-(C ⁇ -C4)alkyl, -O-(C ⁇ -C4)alkyl, -S-(C ⁇ -C3)alkyl, -C5- C20cycloalkyl, -CF3, halo, -NO 2 , and -CN.
  • a prefe ⁇ ed compound of the invention is a compound selected from the group consisting of:
  • More preferred compounds of the invention are represented by the formulae (CI), (C2), (C3), (C4), and (C5):
  • salts may be fo ⁇ ed which are more water soluble and more physiologically suitable than the parent compound.
  • Representative pharmaceutically acceptable salts include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion-exchange resin.
  • salts include the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al, "Pharmaceutical Salts," J. Phar. Sci. cohesive 66: 1-19 (1977)).
  • the basic group(s) of the compound of the invention may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, hydrobromide, camsylate, carbonate, chloride, clavulanate, citrate, chloride, edetate, edisylate, estolate, esylate, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrochloride, hydroxynaphthoate, hydroiodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, o
  • Certain compounds of the invention may possess one or more chiral centers, and thus, may exist in optically active fo ⁇ ns.
  • the compounds may contain an alkenyl or alkenylene group, there exist the possibility of cis- and trans- isomeric forms of the compounds.
  • the R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention.
  • Additional asymmetric carbon atoms can be present in a substjtuent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention.
  • a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.
  • a racemic mixture may be reacted with a single enantiomer of some other compound. This changes the racemic form into a mixture of stereoisomers and diastereomers, because they have different melting points, different boiling points, and different solubilities and can be separated by conventional means, such as crystallization.
  • Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo.
  • Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative forai often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985).
  • Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine.
  • Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferced prodrugs.
  • double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.
  • esters as prodrugs are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, morpholinoethyl, and N,N-diethylglycolamido.
  • N,N-diethylglycolamido ester prodrugs may be prepared by reaction of the sodium salt of a compound of Formula (I) (in a medium such as dimethylformamide) with 2-chloro-N,N-diethylacetamide (available from Aldrich Chemical Co., Milwaukee, Wisconsin USA;. Item No. 25,099-6).
  • Morpholinylethyl ester prodrugs may be prepared by reaction of the sodium salt of a compound of formula (I) (in a medium such as dimethylformamide) with 4-(2- chloroethyl)morpholine hydrochloride (available from Aldrich Chemical Co., Milwaukee, Wisconsin USA, Item No.C4, 220-3).
  • Scheme 1 depicts a protocol for preparing 3-oxo-3H-benzo[d]isoxazole compounds of the invention starting from an aniline derivative 1 ( Aldrich Chemical Co. Milwaukee U.S. A, and other fine chemical suppliers) or substituted analogs thereof.
  • the starting material 1 may be diazotized by reaction with tert-butylnitrite (available from Aldrich Chemical Company, Milwaukee, USA) to afford a diazotized intermediate which reacts with incipient cyanide ion from added copper cyanide to afford the nitrile compound 2.
  • the nitrile 2 is reduced to afford the substituted methylamine compound 3.
  • the substituted methylamine compound 3 is converted to the isocyanate compound 4 in an aprotic solvent such as anhydrous dichloromethane.
  • the conversion of the methylamino compound 3 to the isocyanate compound 4 is accomplished using triphosgene in the presence of a proton scavenger such as triethylamine.
  • a proton scavenger such as triethylamine.
  • the isocyanate 4 or 4' is reacted with a solution of benz[d]isothiazol-3- one in a suitable solvent e.g., anhydrous dichloromethane at temperatures ranging from about 10 to 60 °C.
  • the isocyanate 4or 4' is then reacted with 3-oxo-3H- benzo[ ⁇ f
  • 3-oxo-3H-benzo[ ⁇ i]isoxazole 5 also called 1,2- benzoisothiazolin-3-one is available from commercial suppliers, such as MDA Chemicals Limited, Willow Mill, Caton, Lancaster LA2 9RA, UK. Analogs of 3-oxo- 3H-benzo[ ⁇ i]isoxazole may be obtained by methods described in the examples and/or known to one of skill in the art.
  • the method of the invention for inhibiting hepatic lipase and/or endothelial lipase activity with a therapeutically effective amount of a 3-oxo-3H- benzo[ ]isoxazole carboxamide compound of Fo ⁇ nula (I) including a combination thereof, a salt or a prodrug derivative thereof is as described herein.
  • Another aspect of this invention relates to inhibition or prevention of "Hepatic Lipase Mediated Diseases" such as hypercholesterolemia, hyperlipidemia, stroke, congenital heart failure, hypertension, hypertriglyceridemia, hyper alphaliproteinemia, atherosclerosis and related diseases as described earlier.
  • the method comprises of administering to a mammal (including a human) in need of such treatment a therapeutically effective amount of a 3-oxo-3H-benzo[ ⁇ f]isoxazole carboxamide compound of the invention.
  • the compounds of the invention are useful for inhibiting hepatic lipase and/or endothelial lipase activity.
  • inhibiting is meant to be the prevention or therapeutically significant reduction in release of hepatic lipase and/or endothelial lipase by the compounds of the invention.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the fonm ⁇ ation and not deleterious to the recipient thereof.
  • the specific dose of a compound administered according to this invention to obtain therapeutic or ameliorative or prophylactic effect will, of course, be determined by the particular circumstances surrounding the clinical presentation, including, for example, the compound administered, the route of administration and the condition being treated.
  • Typical daily doses will contain a non-toxic dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of an active compound of this invention.
  • compounds of the invention per Formula (I) or pharmaceutical formulations containing these compounds are in unit dosage forai for administration to a mammal.
  • the unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these.
  • the quantity of Active Ingredient in a unit dose of composition may be varied or adjusted from about 0.1 to about 500 milligrams or more according to the particular treatment involved. It should be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.
  • a compound of the invention may be administered by a variety of routes including oral, aerosol, transdermal, subcutaneous, intravenous, intramuscular, or intranasal as appropriate for the particular patient.
  • compositions of the invention are prepared by combining (e.g., mixing) a therapeutically effective amount of the 3-oxo-3H-benzo[J]isoxazole carboxamide compound of the invention together with a pharmaceutically acceptable carrier or diluent therefor.
  • the present pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients.
  • the Active Ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other container.
  • a carrier which may be in the form of a capsule, sachet, paper or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound.
  • the compounds of the present invention are preferably formulated prior to administration.
  • any suitable carrier known in the art may be used.
  • the carrier may be a solid, liquid, or mixture of a solid and a liquid.
  • the compounds of the invention may be dissolved at a concentration of 2 mg/ml in a 4% dextrose/0.5% Na citrate aqueous solution.
  • Solid form formulations include powders, tablets and capsules.
  • a solid carrier can be one or more substance, which may also act as flavoring agents, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
  • Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or talc.
  • suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate
  • disintegrating agents such as maize, starch, or alginic acid
  • binding agents for example, gelatin or acacia
  • lubricating agents such as magnesium stearate, stearic acid, or talc.
  • a preferred tablet formulation for oral administration is one that affords rapid dissolution in the mouth of a patient in need thereof.
  • the carrier is a finely divided solid, which is in admixture with the finely divided Active Ingredient.
  • the Active Ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape size and color desired.
  • the powders and tablets preferably contain from about 1 to about 99 weight percent of the Active Ingredient(s), which is the novel compound(s) of this invention.
  • Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.
  • Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.
  • the Active Ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both.
  • a pharmaceutically acceptable carrier such as sterile water, sterile organic solvent or a mixture of both.
  • the Active Ingredient may be dissolved in a suitable organic solvent, for instance aqueous propylene glycol.
  • suitable organic solvent for instance aqueous propylene glycol.
  • Other compositions can be made by dispersing the finely divided Active Ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
  • compositions 1 through 8 are illustrative only and are not intended to limit the scope of the invention in any way.
  • Active Ingredient refers to a compound or compounds of Fonriula (I) or a pharaiaceutically acceptable salt, solvate, racemate or enantiomer thereof.
  • Formulation 1 Hard gelatin capsules are prepared using the following ingredients:
  • Active ingredient 250 Starch, dried 200 Magnesium stearate 10 Total 460 mg
  • Formulation 2 A tablet is prepared using the ingredients below:
  • Active Ingredient 250 Cellulose, microcrystalline 400 Silicon dioxide, fumed 10 Stearic acid I Total 665 mg
  • the components are blended and compressed to form tablets each weighing 665 mg
  • Formulation 3 An aerosol solution is prepared containing the following components:
  • the active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to
  • Formulation 4 Tablets each containing 60 mg of Active Ingredient, are made as follows: Active Ingredient 60 mg Starch 45 mg
  • the Active Ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly.
  • the aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve.
  • the granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve.
  • the sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
  • Capsules each containing 80 mg of Active Ingredient, are made as follows:
  • the Active Ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
  • Suppositories each containing 225 mg of Active Ingredient, are made as follows:
  • the Active Ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2g capacity and allowed to cool.
  • Suspensions each containing 50 mg of Active Ingredient per 5 ml dose, are made as follows:
  • the Active Ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste.
  • the benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
  • An intravenous formulation may be prepared as follows:
  • the solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.
  • FAB Fast Atom Bombardment (Mass Spectroscopy)
  • PPA polyphosphoric acid
  • Si ⁇ 2 silica gel
  • Hepatic Lipase Phospholipase Assay Compounds of the present invention were found to be efficacious in-vitro in inhibiting the release of hepatic lipase and/or endothelial lipase. Efficacy was determined by testing various compounds of the invention in a hepatic lipase and/or endothelial lipase assay discussed below, and disclosed in U.S patent application No. 09/609, 871 filed July 3, 2000 incorporated herein in its entirety for U.S Patent office purposes. Reagents
  • Substrate Buffer A 100 niM Hepes, pH 8.3 at 37 °C
  • Substrate Buffer B 100 mM Hepes, pH 8.3 at 37 °C with 6.83 mM Triton X100
  • Thiophospholipid about 0.42 mM thiophospholipid in chlorofom
  • DTNB Solution about 50 nM DTNB in DMSO (dimethyl sulfoxide)
  • Hepes Buffer A there is 2.4 g Hepes/100 mL water. Therefore 36 grams of Hepes is dissolved in 1500 mL of water. The mix solution's pH is adjusted to pH83 at 37° C and brought up to 1500 mL with water. 500 mL of Buffer A is retained for the Protein Buffer.
  • thioPEG/mL of Substrate Buffer B For 0.42 mM substrate stock, use 0.227 mg of thioPEG/mL of Substrate Buffer B. Approximately 20 mg of sn-1 thiol substituted Phosphatidyl Ethyl ene Glycol (see Examples for preparation method) is weighed into a vial, such as a scintillation vial. Enough chloroform should be added to make a 2.043 mg/mL solution. Sonicate the solution briefly until well dissolved. Next, pipette 1 mL of chloroform/substrate solution into each scintillation vial. This should give enough substrate for one full 96 well plate.
  • Each vial is dried with nitrogen until solvent removed, swirling each vial simultaneously such that a thin film of substrate will be easily reconstituted in each buffer. Each vial is then frozen. Daily stock preparation is performed for 9 mL of substrate (one microtiter plate). On the day of the assay, the substrate vial is removed from the freezer and combined with
  • the enzyme is stored at -80 °C in 100 or 50 ⁇ L portions.
  • a 0.406 mg/mL recombinant hepatic lipase and/or endothelial lipase stock requires a 50-fold dilution. Therefore, to a 50 ⁇ l or 100 ⁇ l enzyme aliquot, 2450 ⁇ l or 4900 ⁇ l, respectively, of substrate Buffer A (protein buffer) should be added.
  • the enzyme should then be stored on ice until ready to use.
  • the protein concentration of enzyme is about 0.406 mg/mL.
  • DTNB dimethyl sulfoxide
  • Table 1 below shows final assay volumes and concentrations of various components used following the above procedure.
  • test compound is dissolved in pure DMSO at 1 ⁇ M (1000 nM). As shown below in Table 2, assay concentrations are 10, 1, 0.1, 0.33, 0.011, 0.0037, 0.0012 and 0.00041 ⁇ M. Table 2 shows the assay concentrations and the corresponding volume of stock and 10% DMSO for each concentration.
  • DTNB is used as a thiol coloring reagent with an incubator temperature of 37 °C.
  • Substrate Buffer B is placed in a 37 °C water bath to pre-warm. The substrate is removed from the freezer and 9 mL of substrate Buffer B, 100 mM
  • Hepes, 6.83 mM Tx-100) is added, sonicated for 5 min. and then kept in a 37 °C water bath. Dilutions of the test compound are next made in preparation for assay.
  • Control wells receive 10 ⁇ l each of 10% DMSO and enzyme solution, while blank wells receive 10 microliters of 10% DMSO and 10 microliters of saline (no enzyme).
  • DTNB is weighed and diluted to 20 mg/mL with DMSO. The DTNB is then diluted 10 fold with the substrate Buffer B. 540 ⁇ l of diluted DTNB is added to 9 ml of ThioPEG and mixed well.
  • the stock enzyme is diluted with Buffer A. Next, 10 microliters of protein solution is added to each well except the blank, and the wells mixed. The stock solution and test compounds are incubated at 37 °C for 10 min. At 10 minutes, 80 microliters of substrate are added to each well. The plate is then placed in the spectrometer and read at 412 nM every 2 minutes for 30 minutes.
  • Hepatic lipase (HL) and endothelial lipase (EL) were expressed from AVI 2 cells. Aliquots from one day's collection of media were stored at -70 °C. Activity was measured for both enzymes in conditioned media, (non-purified ) where they were tested on the same plate with Thio PEG substrate (0.06 mol fraction, 7.24 mM total lipid), at 37 °C for 30 minutes.
  • the HL, at lx had an OD of 14.7.
  • the OD for EL at lx was 6.029. Therefore, when HL was used in studies where it was compared to EL, the HL was at 0.25x and EL was used at lx.
  • Temperature of the assay was varied from 26.9 °C to 37 °C with the above- mentioned conditions. This was the temperature of the incubation during the 30-minute read.
  • the pH of the substrate was 8.3.
  • the order of addition of reagents/enzyme was as follows: lO ⁇ L of 10% DMSO, 80 ⁇ L of substrate and 10 ⁇ L of enzyme. Each experiment was ran three times. Data is an average of these experiments.
  • Substrate specificity was determined by testing the activity of HL and EL with Thio Phosphatidylethylene glycol (PEG) and Thio-phosphatidylethanolamine (PE).
  • PEG Thio Phosphatidylethylene glycol
  • PE Thio-phosphatidylethanolamine
  • Assay conditions of assay were as follows. Both substrates for EL were run at 0.03 mol fraction, lOmM total lipid. They were dissolved in lOOmM Hepes with 9.95mM TX100. Both substrates for HL were ran at 0.06 mol fraction and 7.25 mM total lipid. They were dissolved in lOOmM Hepes with 6.83mM Triton XI 00. The EL enzyme was used at lx and the HL enzyme was used at 0.25x. The order of addition was as follows: lO ⁇ L of 10% DMSO, 80 ⁇ L of substrate and 10 ⁇ L of enzyme. The DMSO and substrate were incubated for 10 minutes at 37°C before the addition of the enzyme. DTNB was added to the substrate prior to addition to the well at 0.096 mg/mL final plate concentration. The experiments were performed 3 times. Data represents an average of these.
  • Ethyl isocyanate (92.4 nig, 1.30 mmol) is added to a stirred solution of benzo[ ]isoxazol-3-one (150 mg, 1.10 mmol) in anhydrous THF (4 mL) at ambient temperature under nitrogen. The resultant mixture is heated in an oil bath at 70 °C for 2 hr.
  • title compound 6-3 is obtained as a white solid, mp 46.0-48.0 °C; ESIMS m/e 263 (M+H) + .
  • title compound 6-5 is obtained as a white solid, mp 47.0-48.0 °C; ESIMS m/e 291 (M+H) + .
  • Cyclohexylmethyl amine (0.070 mL, 0.53 mmol) is added dropwise to a stirred suspension of 3-oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 4-nitro-phenyl ester 7 (150 mg, 0.500 mmol) in anhydrous THF (3 mL) at 0 °C under nitrogen to from a clear solution. Then triethyl amine (0.070 mL, 0.50 mmol) is added to the solution and the resultant mixture is allowed to stir at 0 °C for 30 minutes.
  • title compound 6-23 is obtained as a white solid, mp 106.0-107.0 °C; FDMS m/e 282 (M) + .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.

Description

Phospholipase Inhibitors
Field of the Invention This invention relates to novel 3-oxo-3H-benzo[αT]isoxazole carboxamide compounds useful for the treatment and/or prevention of diseases mediated by phospholipases including hepatic and endothelial lipase.
Background of the Invention
Hepatic lipase plays an important role in lipid metabolism. Hepatic lipase is a glycoprotein that functions as a ligand or as an enzyme of approximately 65Kda, which has been shown to catalyze the hydrolysis of lipids including triglycerides, diglycerides and phospholipids in native lipoproteins. It has also been shown to. facilitate the selective uptake of cholesterol from high-density lipoproteins and the removal of remnant particles by the liver (Jonathan C. Cohen, et al Biochemistiy 1992, 31: 8544-8551 and Neve et al Biochemistry J. 1998, 330:701-706).
Other studies showing the inverse relationship of HDL and hepatic lipase activity include for example, Haffiier S.M. et al., "Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy," Metabolism 1983; 32:413-420; Applebaum-Bowden D, et al., "The Dyslipoproteinemia of Anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein -
2 cholesterol," Metabolism 1987; 36:949-952; and Kantor M.A. et al., "Androgens reduce HDL-2 cholesterol and increase hepatic triglyceride lipase activity," Med. Sci. Sport exercise 1985; 17:462-465.
The inverse relationship between hepatic lipase activity and the level of HDL- cholesterol, particularly type-2 HDL-cholesterol, can be used to advantage in up- regulating the Level of HDL cholesterol-the good cholesterol.
Endothelial lipase (EL) is a newly described member of the lipase gene family. Like hepatic lipase, endothelial lipase has been implicated in the hydrolysis of HDL phospholipids and in the reduction of HDL-cholesterol in vivo. In experiments using hepatic lipase knockout mice the infusion of a polyclonal antibody inhibitory to endothelial lipase resulted in a marked increase in HDL- cholesterol levels (Rader, D. J., et al Journal of Clinical Investigation (2003), 111(3) 357-362.
Chan, et al, Proceedings of the National Academy of Sciences U.S.A. (2003), 100(5),' 2748-2753, has also reported the inverse relation between endothelial lipase and HDL-cholesterol.
Given the preceding information, it is desirable to discover and develop compounds that increase HDL levels by methods that may include inhibiting the activity of hepatic lipase and/or endothelial lipase in order to treat, prevent and/or ameliorate the effects of hepatic lipase and/or endothelial lipase mediated diseases. Few therapeutically desirable agents are available to accomplish the task of increasing HDL levels hence the need for and utility of the present invention.
Summary of the Invention The present invention provides a 3-oxo-3H-benzo[fi ]isoxazole carboxamide compound of formula (I):
Figure imgf000003_0001
(I) wherein;
R] is selected from the group consisting of hydrogen, C]-C13alkyl, Cj- C20haloalkyl, C2-C]3alkenyl, C2-C20alkynyl, Cj-Cj jalkoxyalkyl, C]-C]3alkylamine, C\- C5alkylcycloalkyl, Cj-Csalkylcycloalkenyl, cycloalkyl, cycloalkenyl, Cj-C5alkylaryl, C(O)C -C.alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from d-C6alkyl, halo, haloalkyl, COOH, C(O)OC C6alkyl, C(O)Cι-C6alkyl, hydroxy, and amino groups; R is hydrogen; R3, R4 R5, and Rg, are each independently selected from hydrogen, halo, hydroxy, amino, C2-C12alkyl, Ci-C]2haloalkyl, C2-C12alkenyl, C2-Cpalkynyl, C2- C12alkylaryl, Cj-C alkylcycloalkyl, Cj-C^alkylcycloalkenyl, COOH, C(O)C]-C6alkyl, C(O)OCfC6alkyl, C(O)NRaRb, CrC12alkylheterocyclic, phenyl, or aryl; wherein Ra and Rb are independently selected from CrC5alkyl, C2-C5alkenyl, phenyl, benzyl, and C,- C5alkylcycloalkyl; or a pharmaceutically acceptable salt, solvate prodrug or enantiomer thereof.
The present invention provides the use of a 3-oxo-3H-benzo[<i]isoxazole carboxamide compound of formula (I):
Figure imgf000004_0001
(I) wherein
R] is selected from the group consisting of hydrogen, Cj-C]3alkyl, Cχ- C20haloalkyl, C2-C13alkenyl, C2-C20alkynyl, C]-C]3alkoxyalkyl, CrC] 3alkylamine, C\- C5alkylcycloalkyl, C]-C alkylcycloalkenyl, cycloalkyl, cycloalkenyl, C]-C5alkylaryl, C(O)Cj-C6alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from C]-C6alkyl, halo, haloalkyl, COOH, C(O)OC]-C6alkyl, C(O)C C6alkyl, hydroxy, and amino groups;
R2 is hydrogen;
R3, R4 R5, and R5, are each independently selected from hydrogen, halo, hydroxy, amino, C2-C]2alkyl, Cι-C]2haloalkyl, C2-C12alkenyl, C2-C]2alkynyl, C2- C]2alkylaryl, Cj-C^alkylcycloalkyl, CrC]2alkylcycloalkenyl, COOH, C(O)Cf C6alkyl, C(O)OCrC6alkyl, C(O)NRaRb, CrC]2alkylheterocyclic, phenyl, or aryl; wherein Ra and Rb are independently selected from C]-C5alkyl, C2-C5alkenyl, phenyl, benzyl, and C]-C5alkylcycloalkyl; or a pharmaceutically acceptable salt, solvate prodrug or enantiomer thereof for the treatment, prevention and/or amelioration of diseases mediated by hepatic lipase and/or endothelial lipase activity.
The present invention provides the use of 3-oxo-3H-benzo|X]isoxazole-N- carboxamide compounds of formula I as inhibitors of mammalian hepatic lipase and/or endothelial lipase.
The present invention also relates to the use of compounds of formula I useful in the treatment and/or prevention of hepatic lipase and/or endothelial lipase mediated diseases, comprising administration of a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate to a patient in need thereof.
The present invention also relates to the use of a novel 3-oxo-3H- benzo[<i]isoxazole carboxamide compound of formula I to increase or mediate the increase of high-density lipoproteins (HDL) upon administration to a patient in need thereof.
The present invention provides a pharmaceutical composition containing any of the compounds of the invention.
The present invention also relates to the use of a pharmaceutical formulation comprising a compound of formula I and a carrier and/or diluent for the treatment and/or prevention of hypercholesterolemia.
The present invention relates to the use of a compound of fomiula I for the manufacture of a medicament for the treatment and/or prevention of hepatic lipase and/or endothelial lipase-mediated diseases comprising administering a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt, solvate to a patient in need thereof.
Definitions:
The terms, "mammal" and "mammalian" include human and domesticated quadrupeds.
The phrase, "hepatic lipase and/or endothelial lipase mediated-diseases" refers to diseases symptomatic of low HDL levels, caused by, modulated by, exacerbated by or induced directly or indirectly by elevated hepatic lipase and/or endothelial lipase activity, and include for example, hypercholesterolemia, hyperlipidemia, stroke, hypertriglyceridemia, atherosclerosis and related diseases. Treatment and/or prevention of such diseases comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula I in an amount sufficient to inhibit, ameliorate and/or prevent hepatic lipase and/or endothelial lipase activity and to thereby inhibit or prevent the deleterious effects of hepatic lipase and/or endothelial lipase activity.
The term "Active Ingredient" as used herein refers to a compound(s) of Formula (I) or a pharmaceutically acceptable salt, solvate, prodrug, racemate or enantiomer thereof either as the pure compound or delivered as a pharmaceutical formulation or a phaπnaceutical composition. The pharmaceutical composition or formulation containing a compound of the invention and other compound(s) or treatment regimens useful for the treatment and/or prevention of diseases associated with or exacerbated by hepatic lipase and/or endothelial lipase activity (combination drugs) are contemplated to be within the meaning of the term "Active Ingredient(s)."
The term, "3-oxo-3H-benzo[<fjisoxazole", or "3-oxo-3H-benzo[<i]isoxazole nucleus" as used herein refers to a nucleus (having numbered positions) with the structural formula (X):
Figure imgf000006_0001
(X)
The 3-oxo-3H~benzo[J]isoxazole compounds of the invention employ certain defining terms as follows:
The term, "alkyl" by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical, such as for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n- pentyl, and n-hexyl. The term, "alkenyl" employed alone or in combination with other terms means a straight chain or branched monovalent hydrocarbon group having the stated number ranges of carbon atoms, and typified by groups such as vinyl, propenyl, crotonyl, isopentenyl, and various butenyl isomers.
The term, "hydrocarbyl" means an organic group containing only carbon and hydrogen.
The term "carboxy" means an organic group containing only carbon and oxygen, i.e.the group -C(O)-.
The term, "halo" means fluoro, chloro, bromo, or iodo.
The term, "heterocyclic radical" or "heterocyclic group" refers to radicals or groups derived from monocyclic or polycyclic, saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5 to 14 ring atoms and containing from 1 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur. Typical heterocyclic radicals are pyrrolyl, pyrrolodinyl, piperidinyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, benzo(b)thiophenyl, carbazolyl, norharmanyl, azabenzo(b)thiophenyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, indazolyl, imidazo(1.2-A)pyridinyl, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl, benzothiazolyl, purinyl, pyridinyl, dipyridylyl. phenylpyridinyl, benzylpyridinyl, pyrimidinyl, phenylpyrimidinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl, phthalazinyl, quinazolinyl, morpholino, thiomoipholino, homopiperazinyl, tetrahydrofuranyl, tetrahydropyranyl, oxacanyl, 1,3- dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrahydrothiophenyl, pentamethylenesulfadyl, 1,3-dithianyl, 1,4-dithianyl, 1,4-thioxanyl, azetidinyl, hexamethyleneiminium, heptamethyleneiminium, piperazinyl and quinoxalinyl.
The terms "(C1-C12)alkylcyclopentyl," "(C1-C12)alkylcyclohexyl," or "(C5-
C2θ)alkylheterocyclic" represent respectively a (Cj-Ci 2)alkyl, (Cι-Ci2)alkyl, or (Cj- C^alkyl group attached to a cylopentyl, cyclohexyl, and heterocyclic group wherein the entire group is attached to the 3-oxo-3H-benzo[ύ']isoxazole nucleus (X) at the alkyl terminus. The pattern as above is reflective of the naming system or connotation employed herein. For example, the term C]-C) alkylcycloalkyl means the Cι-C12 alkyl group is substituted on the cycloalkyl group and the composite group is attached to the nucleus at the alkyl terminus. For the purpose of the present invention, the term "cycloalkyl" or "(C -C8)cycloalkyl" without more implies a cycloalkyl group having from 3 to 8 carbon atoms.
The term "substituted group" is an organic group substituted with one or more "non-interfering" substituents. By "non-interfering" is meant that the group is suitable chemically and stability-wise to occupy the designated position and perform the designated or intended role. Thus unsuitable groups are excluded from the definition of "non-interfering".
As used herein the terms "group", "radical" or "fragment" are synonymous and are intended to indicate functional groups or fragments of molecules attachable to a bond or other fragments of molecules. For example acetamide group represent the acetamide fragment or radical. Structures of groups, radicals or fragments unattached to the 3-oxo-3H-benzo[< )isoxazole nucleus have been drawn to show the first line as a connecting bond only. Thus, the group
Figure imgf000008_0001
represents the acetamide radical or group, not the propanamide radical unless otherwise indicated.
The term, "alkylene chain of 1 or 2 carbon atoms" refers to the divalent radicals, CH2-CH2- and -CH2-.
The 3-oxo-3H-benzo[ ]isoxazole Compounds of the Invention:
The present invention provides the use of a novel class of 3-oxo-3H- benzo[ύ?]isoxazole compounds useful as inhibitors of hepatic lipase and/or endothelial lipase activity for the treatment, amelioration and/or prevention of hepatic lipase and/or endothelial lipase-mediated diseases.
The compounds of the invention are represented by the general formula (I) and include pharmaceutically acceptable salts, or enantiomers, prodrugs or solvates thereof.
Preferred Subgroups of Compounds of Formula (I): Preferred Ri substituents: The preferred group for R\ is a substituted or unsubstituted group selected from the group consisting of C2-C13alkyl, C -C]3alkenyl, C -Cιoalkoxyalkyl, C5-C] cycloalkenyl, cycohexylmethyl, cyclopentylmethyl, cyclohexylethyl, phenyl, naphthyl, toluyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenyl and cyclohexenyl.
More preferred, as the group R1 is a benzyl group substituted with one, two or three groups independently selected from methyl, ethyl, isopropyl, tert-butyl, isobutyl, methylcyclopentyl, cylopentyl, cyclohexyl, methycyclohexyl, cyclohexylmethyl, cycloheptylmethyl, phenyl and benzyl. Most preferred R\ group is a benzyl group substituted with one, two or three groups independently selected from methyl, ethyl, isopropyl, isobutyl, tert-butyl.
Preferred R3, R4, R5, and Rg substituents:
R3, R4, R5, and R6 are preferably selected independently from the group consisting of hydrogen, halo, hydroxy, amino, Cι-C4alkyl, C2-C4alkenyl, -CO-(Cι- C4)alkyl,-COOH, -COO-(Cι-C4)alkyl, -O-(Cι-C4)alkyl, -S-(Cι-C3)alkyl, -C5- C20cycloalkyl, -CF3, halo, -NO2, and -CN.
A prefeπed compound of the invention is a compound selected from the group consisting of:
3 -oxo-3H-benzo [d] isoxazole- 2-carboxylic acid ethylamide,
3-oxo-3H-benzo[<i]isoxazole- 2-carboxylic acid butylamide,
3-oxo-3H-benzo[J]isoxazole- 2-carboxylic acid hexylamide,
3-oxo-3H-benzo[J]isoxazole- 2-carboxylic acid (5 -methyl -hexyl)amide,
3-oxo-3H-benzo[<i]isoxazole- 2-carboxylic acid (5 -methyl -hexyl)amide,
3-oxo-3H-benzo[<i]isoxazole- 2-carboxylic acid octylamide,
3-oxo-3H-benzo[J]isoxazole- 2-carboxylic acid cyclohexylmethyl-amide,
3 -oxo-3H-benzo [rfjisoxazole- 2-carboxylic acid 4-nitro-phenyl ester,
3-oxo-3H-benzo[rf]isoxazole- 2-carboxylic acid cyclohexylmethyl-amide,
3-oxo-3H-benzo[d]isoxazole- 2-carboxylic acid benzylamide,
3-oxo-3H-benzo[J]isoxazole- 2-carboxylic acid 2-methyl-benzylamide,
3-oxo-3H-benzo[ ]isoxazole- 2-carboxylic acid 3-methyl-benzylamide, 3-oxo-3H-benzo J]isoxazole-2-carboxylic acid 4-methyl-benzylamide, 3-oxo-3H-benzo <i]isoxazole-2- •carboxylic acid 2-trifluoromethyl-benzylamide, 3-oxo-3H-benzo <i]isoxazole ■carboxylic acid 2-fluoro-benzylamide, 3-oxo-3H-benzo djisoxazole ■carboxylic acid 4-fluoro-benzylamide, 3-oxo-3H-benzo JJisoxazole ■carboxylic acid 2-ethyl-benzylamide, 3-oxo-3H-benzo t jisoxazole' -carboxylic acid 3-ethyl-benzylamide, 3-oxo-3H-benzo rfjisoxazole -carboxylic acid 4-te7't-butyl-benzylamide, 3-oxo-3H-benzo d]isoxazole -carboxylic acid 2-isopropyl-6-methyl-benzylamide, 3-oxo-3H-benzo < ]isoxazole -carboxylic acid 3-methoxy-benzylamide, 3-oxo-3H-benzo < ]isoxazole-2- -c< arboxylic acid 4-methoxy-benzylamide, 3-oxo-3H-benzo c?]isoxazole-2- -c< arboxylic acid 2-ethoxy-benzylamide, 3-oxo-3H-benzo d]isoxazole-2- -c< arboxylic acid 3-ethoxy-benzylamide, 3-oxo-3H-benzo ]isoxazole-2- -carboxylic acid 4-ethoxy-benzylamide, 3-oxo-3H-benzo ]isoxazole-2-carboxylic acid phenethyl-amide, and a pharmaceutically acceptable salt, solvate, racemate, enantiomer or diastereomeric mixture thereof.
More preferred compounds of the invention are represented by the formulae (CI), (C2), (C3), (C4), and (C5):
Figure imgf000010_0001
(CI),
Figure imgf000010_0002
(C2),
Figure imgf000011_0001
,(C3),
Figure imgf000011_0002
C5, or a pharmaceutically acceptable salt, solvate, racemate, enantiomer, prodrug or diastereomeric mixture thereof.
The salts of the 3-oxo-3H-benzo[<i]isoxazole carboxamide compounds represented by formula (I), are an additional aspect of the invention.
In those instances when the compound of the invention possesses acidic or basic functional groups, various salts may be foπΗed which are more water soluble and more physiologically suitable than the parent compound. Representative pharmaceutically acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid by treating the acid in solution with a base or by exposing the acid to an ion-exchange resin. Included within the definition of pharmaceutically acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and amine cations, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et al, "Pharmaceutical Salts," J. Phar. Sci.„ 66: 1-19 (1977)). Moreover, the basic group(s) of the compound of the invention may be reacted with suitable organic or inorganic acids to form salts such as acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, hydrobromide, camsylate, carbonate, chloride, clavulanate, citrate, chloride, edetate, edisylate, estolate, esylate, fluoride, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrochloride, hydroxynaphthoate, hydroiodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pantothenate, phosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, tosylate, trifluoroacetate, trifluoromethane sulfonate, and valerate.
Certain compounds of the invention may possess one or more chiral centers, and thus, may exist in optically active foπns. Likewise, when the compounds contain an alkenyl or alkenylene group, there exist the possibility of cis- and trans- isomeric forms of the compounds. The R- and S- isomers and mixtures thereof, including racemic mixtures as well as mixtures of cis- and trans- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substjtuent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods. For example, a racemic mixture may be reacted with a single enantiomer of some other compound. This changes the racemic form into a mixture of stereoisomers and diastereomers, because they have different melting points, different boiling points, and different solubilities and can be separated by conventional means, such as crystallization. Prodrugs are derivatives of the compounds of the invention which have chemically or metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active in vivo. Derivatives of the compounds of this invention have activity in both their acid and base derivative forms, but the acid derivative forai often offers advantages of solubility, tissue compatibility, or delayed release in a mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acidic compound with a suitable alcohol, or amides prepared by reaction of the parent acid compound with a suitable amine. Simple aliphatic or aromatic esters derived from acidic groups pendent on the compounds of this invention are preferced prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy) alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters. Particularly preferred esters as prodrugs are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, morpholinoethyl, and N,N-diethylglycolamido.
N,N-diethylglycolamido ester prodrugs may be prepared by reaction of the sodium salt of a compound of Formula (I) (in a medium such as dimethylformamide) with 2-chloro-N,N-diethylacetamide (available from Aldrich Chemical Co., Milwaukee, Wisconsin USA;. Item No. 25,099-6).
Morpholinylethyl ester prodrugs may be prepared by reaction of the sodium salt of a compound of formula (I) (in a medium such as dimethylformamide) with 4-(2- chloroethyl)morpholine hydrochloride (available from Aldrich Chemical Co., Milwaukee, Wisconsin USA, Item No.C4, 220-3).
Methods for Preparing Compounds of the Invention: Scheme 1
Figure imgf000014_0001
Figure imgf000014_0002
Figure imgf000014_0003
Scheme 1 depicts a protocol for preparing 3-oxo-3H-benzo[d]isoxazole compounds of the invention starting from an aniline derivative 1 ( Aldrich Chemical Co. Milwaukee U.S. A, and other fine chemical suppliers) or substituted analogs thereof. The starting material 1 may be diazotized by reaction with tert-butylnitrite (available from Aldrich Chemical Company, Milwaukee, USA) to afford a diazotized intermediate which reacts with incipient cyanide ion from added copper cyanide to afford the nitrile compound 2. The nitrile 2 is reduced to afford the substituted methylamine compound 3. The substituted methylamine compound 3 is converted to the isocyanate compound 4 in an aprotic solvent such as anhydrous dichloromethane. The conversion of the methylamino compound 3 to the isocyanate compound 4 is accomplished using triphosgene in the presence of a proton scavenger such as triethylamine. The isocyanate 4 or 4' is reacted with a solution of benz[d]isothiazol-3- one in a suitable solvent e.g., anhydrous dichloromethane at temperatures ranging from about 10 to 60 °C. The isocyanate 4or 4' is then reacted with 3-oxo-3H- benzo[<f|isoxazole 5 or substituted analogs thereof to afford the compound(s) of the invention such as compound 6. 3-oxo-3H-benzo[<i]isoxazole 5 also called 1,2- benzoisothiazolin-3-one is available from commercial suppliers, such as MDA Chemicals Limited, Willow Mill, Caton, Lancaster LA2 9RA, UK. Analogs of 3-oxo- 3H-benzo[<i]isoxazole may be obtained by methods described in the examples and/or known to one of skill in the art.
Compounds of formula I wherein all of R3, R4, R5, and Rg are not hydrogen are made starting with purchased starting materials having the requisite substituents or by methods known to one of skill in the art or described in the experimental section.
Methods of Using the Compounds of the Invention:
The 3roxo-3H-benzo[J]isoxazole carboxamide compounds described herein are believed to achieve their beneficial therapeutic action principally by direct inhibition of hepatic lipase and/or endothelial lipase activity.
The method of the invention for inhibiting hepatic lipase and/or endothelial lipase activity with a therapeutically effective amount of a 3-oxo-3H- benzo[ ]isoxazole carboxamide compound of Foπnula (I) including a combination thereof, a salt or a prodrug derivative thereof is as described herein.
Another aspect of this invention relates to inhibition or prevention of "Hepatic Lipase Mediated Diseases" such as hypercholesterolemia, hyperlipidemia, stroke, congenital heart failure, hypertension, hypertriglyceridemia, hyper alphaliproteinemia, atherosclerosis and related diseases as described earlier. The method comprises of administering to a mammal (including a human) in need of such treatment a therapeutically effective amount of a 3-oxo-3H-benzo[<f]isoxazole carboxamide compound of the invention.
As previously noted the compounds of the invention are useful for inhibiting hepatic lipase and/or endothelial lipase activity. By the terai, "inhibiting" is meant to be the prevention or therapeutically significant reduction in release of hepatic lipase and/or endothelial lipase by the compounds of the invention. By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the fonmύation and not deleterious to the recipient thereof.
. The specific dose of a compound administered according to this invention to obtain therapeutic or ameliorative or prophylactic effect will, of course, be determined by the particular circumstances surrounding the clinical presentation, including, for example, the compound administered, the route of administration and the condition being treated. Typical daily doses will contain a non-toxic dosage level of from about 0.01 mg/kg to about 50 mg/kg of body weight of an active compound of this invention.
Preferably, compounds of the invention per Formula (I) or pharmaceutical formulations containing these compounds are in unit dosage forai for administration to a mammal. The unit dosage form can be a capsule or tablet itself, or the appropriate number of any of these. The quantity of Active Ingredient in a unit dose of composition may be varied or adjusted from about 0.1 to about 500 milligrams or more according to the particular treatment involved. It should be appreciated that it may be necessary to make routine variations to the dosage depending on the age and condition of the patient. The dosage will also depend on the route of administration.
A compound of the invention may be administered by a variety of routes including oral, aerosol, transdermal, subcutaneous, intravenous, intramuscular, or intranasal as appropriate for the particular patient.
Pharmaceutical formulations of the invention are prepared by combining (e.g., mixing) a therapeutically effective amount of the 3-oxo-3H-benzo[J]isoxazole carboxamide compound of the invention together with a pharmaceutically acceptable carrier or diluent therefor. The present pharmaceutical formulations are prepared by known procedures using well-known and readily available ingredients.
In making the compositions of the present invention, the Active Ingredient will usually be admixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), or ointment, containing, for example, up to 10% by weight of the active compound. The compounds of the present invention are preferably formulated prior to administration.
For the phaπnaceutical formulations any suitable carrier known in the art may be used. In such a formulation, the carrier may be a solid, liquid, or mixture of a solid and a liquid. For example, for intravenous injection the compounds of the invention may be dissolved at a concentration of 2 mg/ml in a 4% dextrose/0.5% Na citrate aqueous solution. Solid form formulations include powders, tablets and capsules. A solid carrier can be one or more substance, which may also act as flavoring agents, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
Tablets for oral administration may contain suitable excipients such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, together with disintegrating agents, such as maize, starch, or alginic acid, and/or binding agents, for example, gelatin or acacia, and lubricating agents such as magnesium stearate, stearic acid, or talc. A preferred tablet formulation for oral administration is one that affords rapid dissolution in the mouth of a patient in need thereof.
In powders the carrier is a finely divided solid, which is in admixture with the finely divided Active Ingredient. In tablets the Active Ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape size and color desired. The powders and tablets preferably contain from about 1 to about 99 weight percent of the Active Ingredient(s), which is the novel compound(s) of this invention. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethyl cellulose, low melting waxes, and cocoa butter.
Sterile liquid form formulations include suspensions, emulsions, syrups and elixirs.
The Active Ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent or a mixture of both. The Active Ingredient may be dissolved in a suitable organic solvent, for instance aqueous propylene glycol. Other compositions can be made by dispersing the finely divided Active Ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
The following pharmaceutical formulations 1 through 8 are illustrative only and are not intended to limit the scope of the invention in any way. "Active Ingredient", refers to a compound or compounds of Fonriula (I) or a pharaiaceutically acceptable salt, solvate, racemate or enantiomer thereof. Formulation 1 Hard gelatin capsules are prepared using the following ingredients:
Quantity
(mg/eapsule
Active ingredient 250 Starch, dried 200 Magnesium stearate 10 Total 460 mg
Formulation 2 A tablet is prepared using the ingredients below:
Quantity (mg/tablef)
Active Ingredient 250 Cellulose, microcrystalline 400 Silicon dioxide, fumed 10 Stearic acid I Total 665 mg
The components are blended and compressed to form tablets each weighing 665 mg
Formulation 3 An aerosol solution is prepared containing the following components:
Weight
Active Ingredient 0.25
Ethanol 25.75
Propellant 22 (Chlorodifluoromethane) 74.00
Total 100.00
The active compound is mixed with ethanol and the mixture added to a portion of the propellant 22, cooled to
-30°C and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the remainder of the propellant. The valve units are then fitted to the container.
Formulation 4 Tablets, each containing 60 mg of Active Ingredient, are made as follows: Active Ingredient 60 mg Starch 45 mg
Microcrystalline cellulose 35 mg
Polyvinylpyrrolidone (as 10% solution in water) 4 mg
Sodium carboxymethyl starch 4.5 mg
Magnesium stearate 0.5 mg
Talc 1 mg
Total 150 mg
The Active Ingredient, starch and cellulose are passed through a No. 45 mesh U.S. sieve and mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the mixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50°C and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate and talc, previously passed through a No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation 5
Capsules, each containing 80 mg of Active Ingredient, are made as follows:
Active Ingredient 80 mg
Starch 59 mg
Microcrystalline cellulose 59 mg
Magnesium stearate 2 mg
Total 200 mg
The Active Ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Foraiulation 6
Suppositories, each containing 225 mg of Active Ingredient, are made as follows:
Active Ingredient 225 mg
Saturated fatty acid glycerides 2,000 mg
Total 2,225 mg
The Active Ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2g capacity and allowed to cool.
Formulation 7
Suspensions, each containing 50 mg of Active Ingredient per 5 ml dose, are made as follows:
Active Ingredient 50 mg
Sodium carboxymethyl cellulose 50 mg
Syrup 1.25 ml
Benzoic acid solution 0.10 ml
Flavor q.v.
Color q.v.
Purified water to total 5 ml
The Active Ingredient is passed through a No. 45 mesh U.S. sieve and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Formulation 8
An intravenous formulation may be prepared as follows:
Active Ingredient 100 mg
Isotonic saline 1 ,000 ml
The solution of the above ingredients generally is administered intravenously to a subject at a rate of 1 ml per minute.
The abbreviations, symbols and terms used in the examples have the following meanings. Ac = acetyl
Anal. = elemental analysis calcd = calculated Cpd. = compound DMF = dimethylformamide DMSO = dimethylsulfoxide Et = ethyl EtOAc = ethyl acetate
EtOH = ethanol
EtSH = ethanethiol
•ESIMS = Electrospray Ionization Mass Spectrometry
FAB = Fast Atom Bombardment (Mass Spectroscopy)
FDMS = field desorption mass spectrum
Hex = hexanes
HL = Hepatic Lipase
HPLC = High Performance Liquid Cliromatograph
HRMS = high resolution mass spectrum
IR = Infrared Spectrum .
Me = methyl
Mel = methyl iodide
MeOH = methanol
MPLC = Medium Pressure Liquid Chromatography
NMR = Nuclear Magnetic Resonance
PPA = polyphosphoric acid
Rochelle's Salt = potassium sodium tartrate
RPHPLC = Reversed Phase High Performance Liquid Chromatography
Siθ2 = silica gel
SM = starting material
Temp. - temperature
TFA = trifluoroacetic acid
THF = tetrahydrofuran
TLC = thin layer chromatography
Hepatic Lipase Phospholipase Assay Compounds of the present invention were found to be efficacious in-vitro in inhibiting the release of hepatic lipase and/or endothelial lipase. Efficacy was determined by testing various compounds of the invention in a hepatic lipase and/or endothelial lipase assay discussed below, and disclosed in U.S patent application No. 09/609, 871 filed July 3, 2000 incorporated herein in its entirety for U.S Patent office purposes. Reagents
Substrate Buffer A: 100 niM Hepes, pH 8.3 at 37 °C
Substrate Buffer B: 100 mM Hepes, pH 8.3 at 37 °C with 6.83 mM Triton X100
ThioPEG: Molecular wt. of 540
Recombinant Hepatic Lipase
Thiophospholipid: about 0.42 mM thiophospholipid in chlorofom
DTNB Solution: about 50 nM DTNB in DMSO (dimethyl sulfoxide)
Hepes Buffer A
For Hepes Buffer A, there is 2.4 g Hepes/100 mL water. Therefore 36 grams of Hepes is dissolved in 1500 mL of water. The mix solution's pH is adjusted to pH83 at 37° C and brought up to 1500 mL with water. 500 mL of Buffer A is retained for the Protein Buffer.
Hepes Buffer B
To the remaining 1000 mL of Hepes Buffer A, 4.49 g of Triton X-100 is added and then the combination mixed on a stir plate. It is optimal that stock Buffer A not be too cold or Triton X-100 will take a long time to go into solution
ThioPEG Substrate Solution
For 0.42 mM substrate stock, use 0.227 mg of thioPEG/mL of Substrate Buffer B. Approximately 20 mg of sn-1 thiol substituted Phosphatidyl Ethyl ene Glycol (see Examples for preparation method) is weighed into a vial, such as a scintillation vial. Enough chloroform should be added to make a 2.043 mg/mL solution. Sonicate the solution briefly until well dissolved. Next, pipette 1 mL of chloroform/substrate solution into each scintillation vial. This should give enough substrate for one full 96 well plate. Each vial is dried with nitrogen until solvent removed, swirling each vial simultaneously such that a thin film of substrate will be easily reconstituted in each buffer. Each vial is then frozen. Daily stock preparation is performed for 9 mL of substrate (one microtiter plate). On the day of the assay, the substrate vial is removed from the freezer and combined with
9 mL of pre-warmed (37 °C) substrate buffer (the final concentration is 0.227 mg/mL). Place the buffer in a 37°C water bath. Sonicate for 5 minutes or vortex until solution is clear before use.
Enzyme Solution
The enzyme is stored at -80 °C in 100 or 50 μL portions. A 0.406 mg/mL recombinant hepatic lipase and/or endothelial lipase stock requires a 50-fold dilution. Therefore, to a 50 μl or 100 μl enzyme aliquot, 2450 μl or 4900 μl, respectively, of substrate Buffer A (protein buffer) should be added. The enzyme should then be stored on ice until ready to use. The protein concentration of enzyme is about 0.406 mg/mL.
DTNB Solution
To make a 20 mg/mL stock solution, 2-3 mg of DTNB is weighed and then mixed with an appropriate amount of 100% DMSO (dimethyl sulfoxide) to make the desired concejitration. This mixture is sonicated for five minutes.
The above solution should be diluted 10 fold with substrate Buffer B (concentration now 2 mg/mL). Then to the thioPEG substrate solution, add 60 μl of dilute DTNB per mL of thioPEG substrate solution. Thus for 9 mL of substrate, 540 microliters of dilute DTNB (final concentration in substrate solution = 0.11 mg/mL).
Table 1 below shows final assay volumes and concentrations of various components used following the above procedure.
Figure imgf000023_0001
Table 1 : Final Assay Volumes and Concentrations Hepatic Lipase Phospholipase Assay
Sample Preparation
The test compound is dissolved in pure DMSO at 1 μM (1000 nM). As shown below in Table 2, assay concentrations are 10, 1, 0.1, 0.33, 0.011, 0.0037, 0.0012 and 0.00041 μM. Table 2 shows the assay concentrations and the corresponding volume of stock and 10% DMSO for each concentration.
Figure imgf000024_0001
Table 2: Assay concentrations for compound preparation
Assay Procedure
Using a spectrometer, DTNB is used as a thiol coloring reagent with an incubator temperature of 37 °C. Substrate Buffer B is placed in a 37 °C water bath to pre-warm. The substrate is removed from the freezer and 9 mL of substrate Buffer B, 100 mM
Hepes, 6.83 mM Tx-100) is added, sonicated for 5 min. and then kept in a 37 °C water bath. Dilutions of the test compound are next made in preparation for assay.
10 μl of the diluted test compound are transferred via pipette into the wells. Control wells receive 10 μl each of 10% DMSO and enzyme solution, while blank wells receive 10 microliters of 10% DMSO and 10 microliters of saline (no enzyme).
Next, DTNB is weighed and diluted to 20 mg/mL with DMSO. The DTNB is then diluted 10 fold with the substrate Buffer B. 540 μl of diluted DTNB is added to 9 ml of ThioPEG and mixed well.
The stock enzyme is diluted with Buffer A. Next, 10 microliters of protein solution is added to each well except the blank, and the wells mixed. The stock solution and test compounds are incubated at 37 °C for 10 min. At 10 minutes, 80 microliters of substrate are added to each well. The plate is then placed in the spectrometer and read at 412 nM every 2 minutes for 30 minutes.
Results of hepatic lipase inhibition assay
Figure imgf000025_0001
Characterization of endothelial lipase activity
Hepatic lipase (HL) and endothelial lipase (EL) were expressed from AVI 2 cells. Aliquots from one day's collection of media were stored at -70 °C. Activity was measured for both enzymes in conditioned media, (non-purified ) where they were tested on the same plate with Thio PEG substrate (0.06 mol fraction, 7.24 mM total lipid), at 37 °C for 30 minutes. The HL, at lx, had an OD of 14.7. The OD for EL at lx was 6.029. Therefore, when HL was used in studies where it was compared to EL, the HL was at 0.25x and EL was used at lx. All experiments were done in triplicate with enzyme from conditioned media. Kinetic experiments for EL were done varying the total lipid with a constant 0.044 mol fraction determining that a lOmM total lipid was optimal. In addition, kinetic experiments varying the mol fractions with a constant total lipid showed that 0.03 mol fraction was optimal. Each experiment was ran three times.
Experiments to determine proper pH of the substrate to be used with EL were performed at 37 °C with the above-mentioned conditions. The enzyme was tested at pH 7.0, 7.4 and 8.3. The order of addition of reagents/enzyme was as follows: lOμL of 10% DMSO, 80 μL of substrate and 10 μL of enzyme. Data represents an average of three experiments.
Temperature of the assay was varied from 26.9 °C to 37 °C with the above- mentioned conditions. This was the temperature of the incubation during the 30-minute read. The pH of the substrate was 8.3. The order of addition of reagents/enzyme was as follows: lOμL of 10% DMSO, 80 μL of substrate and 10 μL of enzyme. Each experiment was ran three times. Data is an average of these experiments.
Substrate specificity was determined by testing the activity of HL and EL with Thio Phosphatidylethylene glycol (PEG) and Thio-phosphatidylethanolamine (PE).
Assay conditions of assay were as follows. Both substrates for EL were run at 0.03 mol fraction, lOmM total lipid. They were dissolved in lOOmM Hepes with 9.95mM TX100. Both substrates for HL were ran at 0.06 mol fraction and 7.25 mM total lipid. They were dissolved in lOOmM Hepes with 6.83mM Triton XI 00. The EL enzyme was used at lx and the HL enzyme was used at 0.25x. The order of addition was as follows: lOμL of 10% DMSO, 80 μL of substrate and 10 μL of enzyme. The DMSO and substrate were incubated for 10 minutes at 37°C before the addition of the enzyme. DTNB was added to the substrate prior to addition to the well at 0.096 mg/mL final plate concentration. The experiments were performed 3 times. Data represents an average of these.
While the present invention has been illustrated above by certain specific embodiments, it is not intended that these specific embodiments should limit the scope of the invention as described in the appended claims. Experimental All of the products of the Examples described below as well as intermediates used in the following procedures showed satisfactory NMR and IR spectra. They also had the corcectmass spectral values.
Example 1 3-Oxo-3H-benzo[t/]isoxazole-2-carboxylic acid ethylamide
Figure imgf000027_0001
6-1
Ethyl isocyanate (92.4 nig, 1.30 mmol) is added to a stirred solution of benzo[ ]isoxazol-3-one (150 mg, 1.10 mmol) in anhydrous THF (4 mL) at ambient temperature under nitrogen. The resultant mixture is heated in an oil bath at 70 °C for 2 hr. After concentration and subsequent flash chromatography on silica (15% hexane in CH2C12), 6-1 is obtained as a white solid (170 mg, 75% yield), mp 112.0-113.0 °C; 1H- NMR (CDC13) £1.28 (t, J= 7.3 Hz, 3H), 3.43-3.51 (m, 2H), 7.21-7.29 (m, 3H), 8.04 (br s, 1H), 8.07 (d, J= 6.8 Hz, 1H); ESIMS m/e 207 (M+H)+. Analysis for C10H10N2O3: calcd: C, 58.25; H, 4.89; N, 13.59; found: C, 58.04; H, 4.82; N, 13.41.
Example 2
3-Oxo-3H-benzo[ci]isoxazole-2-carboxylic acid butylamide
Figure imgf000027_0002
6-2
By following similar procedure as described in Example 1 , title compound 6-2 (66% yield) is obtained as a white solid, mp 64.0-65.0 °C; ESIMS m/e 235 (M+H)+. Analysis for Cι2H]4N2O3: calcd: C, 61.53; H, 6.02; N, 11.96; found: C, 61.30; H, 6.24; N, 11.97. Example 3
3-Oxo-3H-benzo[ύT]isoxazole-2-carboxylic acid hexylamide
Figure imgf000028_0001
6-3
By following similar procedure as described in Example 1 , title compound 6-3 is obtained as a white solid, mp 46.0-48.0 °C; ESIMS m/e 263 (M+H)+.
Example 4
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid (5-methyl-hexyl)amide
Figure imgf000028_0002
6-4
A. Preparation of (l-isocyanato-5-methyl)-hexane
,NCO
4
A solution of 5-(methyl)hexylamine (407 mg, 3.53 mmol) and proton sponge (1.51 g, 7.06 mmol) in anhydrous CH2C12 (6 mL) is added dropwise to a stirred solution of triphosgene (419 mg, 1.41 mmol) in anhydrous CH C12 (6 mL) at 0 °C. The resultant solution is allowed to stir at ambient temperature for 15 minutes. After dilution with CH2C12 (40 mL), the mixture was washed with IN HC1 (15x2 mL) and water (15 mL). The organic layer is dried over Na2SO4, filtered and concentrated to give the desired isocyanate 4 (365 mg, 73% yield) as oil. 1H-NMR (CDC13) £0.88 (d, J= 6.6 Hz, 6H), 1.16-1.23 (m, 2H), 1.32-1.42 (m, 2H), 1.50-1.62 (m, 3H), 3.29 (t, J= 6.6 Hz, 2H).
B. Preparation of 3-oxo-3H-benzo[< ]isoxazole-2-carboxylic acid (5-methyl-hexyl)amide
Figure imgf000029_0001
6-4
By following similar procedure as described in Example 1 , title compound 6-4 is obtained as a white solid, mp 73.0-75.0 °C; 1H-NMR (DMSO-d6) £0.84 (d, J= 6.6 Hz, 6H), 1.14-1.20 (m, 2H), 1.26-1.34 (m, 2H), 1.47-1.55 (m, 3H), 3.26-3.31 (m, 2H), 7.22- 7.29 (m, 2H), 7.38-7.41 (m, IH), 7.86-7.89 (m, IH), 8.11 (t, J= 5.5 Hz, IH); FDMS m/e 276 (M)+. Analysis for C15H20N2O3: calcd: C, 65.20; H, 7.30; N, 10.14; found: C, 65.22; H, 7.39; N, 10.18.
Example 5
3-Oxo-3H-benzo[<i]isoxazole-2-carboxylic acid octylamide
Figure imgf000029_0002
6-5
By following similar procedure as described in Example 1 , title compound 6-5 is obtained as a white solid, mp 47.0-48.0 °C; ESIMS m/e 291 (M+H)+.
Example 6
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid cyclohexylmethyl-amide
Figure imgf000029_0003
6-6 A. Preparation of 3-oxo-3H-benzo[<i]isoxazole-2-carboxylic acid 4-nitro-phenyl ester
Figure imgf000030_0001
7 A solution of 4-nitrophenyl chloroformate (1.63 g, 7.80 mmol) in anhydrous THF (20 mL) is added to a stirred solution of benzo[ ]isoxazol-3-one (1.06 g, 7.80 mmol) in anhydrous THF (20 mL) at 0 °C under nitrogen. Then NEt3 (1.19 mL, 8.50 mmol) is added dropwise to the stin-ed mixture at 0 °C to form a white suspension. After stirring at 0 °C for 10 minutes, the mixture is filtered and the filtrate is concentrated at ambient temperature in vacuo to give a white solid. The white solid is dissolved in EtOAc (80 . mL) and the solution is washed with H2O (25 mL x 3), dried over Na2CO3, filtered and concentrated to give a white solid. After recrystallization in THF/hexane, the title compound 7 is obtained as a white solid (1.46 g, 63%> yield). Which is used for the subsequent reaction.
B. Preparation of 3-oxo-3H-benzo[ ]isoxazole-2-carboxylic acid cyclohexylmethyl- amide
Figure imgf000030_0002
6-6
Cyclohexylmethyl amine (0.070 mL, 0.53 mmol) is added dropwise to a stirred suspension of 3-oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 4-nitro-phenyl ester 7 (150 mg, 0.500 mmol) in anhydrous THF (3 mL) at 0 °C under nitrogen to from a clear solution. Then triethyl amine (0.070 mL, 0.50 mmol) is added to the solution and the resultant mixture is allowed to stir at 0 °C for 30 minutes. The mixture is concentrated and the crade product is chromato graphed on silica (gradient 10-30% EtOAc in hexane) to give the title compound 6-6 as a white solid, mp 82.0-84.0 °C; ESIMS m/e 275 (M+H)+. Example 7
3-Oxo-3H-benzo[Jjisoxazole-2-carboxylic acid benzylamide
Figure imgf000031_0001
6-7 By following similar procedure as described in Example 1 , title compound 6-7 is obtained as a white solid, mp 124.0-125.0 °C; ESIMS m/e 269 (M+H)+.
Example 8
3-Oxo-3H-benzo[<i]isoxazole-2-carboxylic acid 2-methyl-benzylamide
6-8
By following similar procedure as described in Example 6, title compound 6-8 is obtained as a white solid, mp 154.0-155.0 °C; ESIMS m/e 283 (M+Η)+.
Example 9
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 3-methyl-benzylamide
Figure imgf000031_0003
6-9 By following similar procedure as described in Example 6, title compound 6-9 is obtained as a white solid, mp 110.0-112.0 °C; ESIMS m/e 283 (M+H)+. Analysis for Cι6Hι4N2O3: calcd: C, 68.08; H, 5.00; N, 9.92; found: C, 67.89; H, 4.95; N, 10.10.
Example 10
3-Oxo-3H-benzo[<f]isoxazole-2-carboxylic acid 4-methyl-benzylamide
Figure imgf000032_0001
6-10
By following similar procedure as described in Example 6, title compound 6-10 is obtained as a white solid. ESIMS m/e 283 (M+H)+.
Example 11
3-Oxo-3H-benzo[d]isoxazole-2-carboxylic acid 2-trifluoiOinethyl-benzylamide
Figure imgf000032_0002
6-11
By following similar procedure as described in Example 6, title compound 6-11 is obtained as a white solid, mp 139.0-141.0 °C; ESIMS m/e 337 (M+H)+. Analysis for Cι6HιιF3N2O3: calcd: C, 57.15; H, 3.30; N, 8.33; found: C, 57.13; H, 3.32; N, 8.32.
Example 12
3-Oxo-3H-benzo[<i]isoxazole-2-carboxylic acid 2-fluoro-benzylamide
Figure imgf000033_0001
6-12
By following similar procedure as described in Example 6, title compound 6-12 is obtained as a white solid, mp 142.0-143.Q °C; ESIMS m/e 287 (M+H)+.
Example 13
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 4-fluoro-benzylamide
Figure imgf000033_0002
6-13
By following similar procedure as described in Example 6, title compound 6-13 is obtained as oil. FDMS m/e 286 (M)+.
Example 14
3-Oxo-3H-benzo[(i]isoxazole-2-carboxylic acid 2-ethyl-benzylamide
Figure imgf000033_0003
6-14
By following similar procedure as described in Example 6, title compound 6-14 is obtained as a white solid, mp 107.0-109.0 °C; ESIMS m/e 314 (M+NH4)+. Analysis for C]7H]6N2O3: calcd: C, 68.91; H, 5.44; N, 9.45; found: C, 69.09; H, 5.57; N, 9.39. Example 15
3-Oxo-3H-benzo[«Jjisoxazole-2-carboxylic acid 3 -ethyl -benzylamide
6-15
By following similar procedure as described in Example 6, title compound 6-15 is obtained as a white solid, mp 72.0-73.0 °C; FDMS m/e 296 (M)\ Analysis for C]7H]6N2O3: calcd: C, 68.91; H, 5.44; N, 9.45; found: C, 69.07; H, 5.53; N, 9.40.
Example 16
3-Oxo-3H-benzo[d]isoxazole-2-carboxylic acid 4-tert-butyl-benzylamide
Figure imgf000034_0002
6-16
By following similar procedure as described in Example 6, title compound 6-16 is obtained as a white solid, mp 123.0-125.0 °C; FDMS m/e 325 (M+Η)+.
Example 17
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide
Figure imgf000034_0003
6-17 A. The preparation of 2-isopropyl-6-methyl-benzonitrile
Figure imgf000035_0001
2 CuCN (7.80 g, 87.2 mmol) is added to a stirred anhydrous DMSO (70 mL) at 60 °C to form a clear solution, then followed by the addition of t-BuNO (24.0 mL, 202 mmol) all at once. A solution of 2-isopropyl-6-menthylaniline (10.0 g, 67.0 mmol) in anhydrous DMSO (30 mL) is added dropwise, via an addition funnel, to the mixture. After the addition is complete, the reaction mixture is allowed to stir for 1 hr. After being cooled to 45 °C, the mixture is slowly treated with 5N HCl (100 mL). Five minutes later, the reaction mixture is cooled to ambient temperature before it is extracted with EtOAc/hexane (1:1; 500x2 mL). The combined organic layers are washed with water (100 mL) and brine (100 mL), dried, concentrated in vacuo, then chromatographed on silica (0-5%o EtOAc in hexane) to give 8.43 g of the crude nitrile 2. IR(CHC13) 2220 cm" ]; 1H-NMR (CDC13) £1.30 (d, J= 6.9 Hz, 6H), 2.54 (s, 3H), 3.38 (h, J= 6.9 Hz, IH), 7.13 (br d, J= 7.8 Hz, IH), 7.20 (br d, J= 7.8 Hz, IH), 7.41 (br t, J= 7.8 Hz, IH); ESIMS m/e 160 (M+H)+.
B. The preparation of 2-isopropyl-6-methyl-benzylamine
Figure imgf000035_0002
3 To the crude ice-cold nitrile 2 (7.74 g, 48.6 mmol) in anhydrous Et O (70 mL) is slowly added lithium aluminum hydride (IN in Et2O, 97.2 mL) under nitrogen. The resultant mixture is allowed to stir at ambient temperature for 16 hr. Then the reaction mixture is cooled at 0 °C and quenched with MeOH until the gas evolution stops. EtOAc (500 mL) and saturated aqueous Rochelle's salt are added and the two-layered mixture is stiπed vigorously under nitrogen for 1 hr to give two relatively clear layers. The organic layer is separated, dried over MgSO4, filtered and concentrated, the crade oil is chromatographed on silica [20% EtOAc in hexane, then 1-2% (4.2 M Me3N in EtOH) in CHC13]. Amine 3 (3.78 g, yield 48%) is obtained as a brown oil. IR(CHC13) 3300(br) cm'1; 1H-NMR (CDCI3) £1.16 (d, J= 6.8 Hz, 6H), 1.55 (br s, 2H), 2.33 (s, 3H), 3.28 (h, J = 6.8 Hz, IH), 3.71 (s, 2H), 6.92-6.95 (m, IH), 7.03-7.10 (m, 2H); ESIMS m/e 164 (M+H)+.
C. The preparation of 3-oxo-3H-benzo[ύT]isoxazole-2-carboxylic acid 2-isopropyl-6- methyl-benzylamide
Figure imgf000036_0001
6-17
By following similar procedure as described in Example 6, title compound 6-17 is obtained as a white solid, mp 112.0-114.0 °C; FDMS m/e 324 (M)+. Analysis for C19H20N2O3: calcd: C, 70.35; H, 6.21; N, 8.64; found: C, 70.37; H, 6.30; N, 8.58.
Example 18
3-Oxo-3H-benzo[rf]isoxazole-2-carboxylic acid 3-methoxy-benzylamide
Figure imgf000036_0002
6-18
By following similar procedure as described in Example 6, title compound 6-18 is obtained as a white solid, mp 99.0-100.0 °C; ESIMS m/e 299 (M+H)+.
Example 19
3-Oxo-3H-benzo[< jisoxazole-2-carboxylic acid 4-methoxy-benzylamide
Figure imgf000037_0001
6-19
By following similar procedure as described in Example 6, title compound 6-19 is obtained as a white solid, mp 140.0-141.0 °C; FDMS m/e 298 (M)+.
Example 20
3-Oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 2-ethoxy-benzylamide
Figure imgf000037_0002
6-20
By following similar procedure as described in Example 6, title compound 6-20 is obtained as a white solid, mp 110.0-112.0 °C; ESIMS m/e 313 (M+H)+. Analysis for Cι7Hι6N2O4: calcd: C, 65.38; H, 5.16; N, 8.97; found: C, 65.33; H, 5.21; N, 8.86.
Example 21
3-Oxo-3H-benzo[t |isoxazole-2-carboxylic acid 3-ethoxy-benzylamide.
Figure imgf000037_0003
6-21
By following similar procedure as described in Example 6, title compound 6-21 is obtained as a white solid, mp 89.0-90.0 °C; ESIMS m/e 313 (M+H)+. Analysis for C,7H16N2O4: calcd: C, 65.38; H, 5.16; N, 8.97; found: C, 65.32; H, 5.18; N, 8.83. Example 22 3-Oxo-3H-benzo[J]isoxazole-2-carboxylic acid 4-ethoxy-benzylamide
Figure imgf000038_0001
6-22
By following similar procedure as described in Example 6, title compound 6-22 is obtained as a white solid, mp 110.0.112.0 °C; FDMS m/e 312 (M)+. Analysis for C)7Hι6N2O4: calcd: C, 65.38; H, 5.16; N, 8.97; found: C, 65.17; H, 5.17; N, 8.93.
Example 23
3-Oxo-3H-benzo[<i]isoxazole-2-carboxylic acid phenethyl-amide
Figure imgf000038_0002
6-23
By following similar procedure as described in Example 1 , title compound 6-23 is obtained as a white solid, mp 106.0-107.0 °C; FDMS m/e 282 (M)+.

Claims

WE CLAIM:
A 3-oxo-3H-benzo[ύT]isoxazole carboxamide compound of formula (I):
Figure imgf000039_0001
(I) wherein;
Ri is selected from the group consisting of hydrogen, Cj-C]3alkyl, Cj- C20haloalkyl, C2-C13alkenyl, C2-C20alkynyl, C C]3alkoxyalkyl, Cj-C^alkylamine, - C5alkylcycloalkyl, Ci-Csalkylcycloalkenyl, cycloalkyl, cycloalkenyl, Cj-C5alkylaryl, C(O)C1-C(.alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from C]-C6alkyl, halo, haloalkyl, COOH, C(O)OCι-C6alkyl, C(O)Cι-C6alkyl, hydroxy, and amino groups;
R is hydrogen; R3, R4 R5, and R6, are each independently selected from hydrogen, halo, hydroxy, amino, C2-C]2alkyl, Cι-C]2haloalkyl, C2-C]2alkenyl, C2-C]2alkynyl, C2-C]2alkylaryl, CrC12alkylcycloalkyl, C C12alkylcycloalkenyl, COOH, C(O)C]-C6alkyl, C(O)OCr C6alkyl, C(O)NRaRb, CrC12alkylheterocyclic, phenyl, or aryl; wherein Ra and Rb are independently selected from C]-C5alkyl, C2-C5alkenyl, phenyl, benzyl, and Cj- C5alkylcycloalkyl; or a pharmaceutically acceptable salt, solvate prodrug or enantiomer thereof.
2. Use of a 3-oxo-3H-benzo[d isoxazole carboxamide compound of formula (I):
Figure imgf000040_0001
(I) wherein
R] is selected from the group consisting of hydrogen, C]-C]3alkyl, C,- C20haloalkyl, C2-C13alkenyl, C2-C20alkynyl, CrC]3alkoxyalkyl, Cj-C^alkylamine, d- C5alkylcycloalkyl, Ci-Csalkylcycloalkenyl, cycloalkyl, cycloalkenyl, Cj-C5alkylaryl, C(O)C1-C6alkyl, and alkylheterocyclic radical; wherein each of the alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and heterocyclic groups may be further substituted with 1, 2, or 3 substituents independently selected from C]-C6alkyl, halo, haloalkyl, COOH, C(O)OC]-C6alkyl, C(O)d-C6alkyl, hydroxy, and amino groups;
R is hydrogen; R3, R4 R5, and R , are each independently selected from hydrogen, halo, hydroxy, amino, C2-C]2alkyl, Cι-C12haloalkyl, C2-C]2alkenyl, C2-C]2alkynyl, C2-C]2alkylaryl, CfC12alkylcycloalkyl, CfC]2alkylcycloalkenyl, COOH, C(O)CrC6alkyl, C(O)OCf C6alkyl, C(O)NRaRb, Cj-C]2alkylheterocyclic, phenyl, or aryl; wherein Ra and Rb are independently selected from CrC5alkyl, C2-C5alkenyl, phenyl, benzyl, and Cj- C5alkylcycloalkyl; or a pharmaceutically acceptable salt, solvate prodrug or enantiomer thereof, for the treatment, prevention and/or amelioration of diseases mediated by hepatic lipase and/or endothelial lipase activity.
3. A compound of Claim 1 wherein Rj is selected from (C3-C13)alkyl, (C3-Ci4)alkenyl, (C3-C4)cycloalkyl, substituted or unsubstituted benzyl.
4. A compound according to Claim 1, wherein Ri is 1,5-disubstituted benzyl with substituents independently selected from methyl, ethyl, propyl, isopropyl, isobutyl, and tert-butyl.
5. A compound of Claim I wherein R3, R4, R5 and Rg are independently selected from hydrogen, (Ci -C^alkyl, (C2-C4)alkenyl, COOH, C(O)OC,_-C6alkyl, , C(O)CfC6alkyl -O-(Cι-C3 alkyl), -S-(C!-C3 alkyl), (C5-C2o)cycloalkyl, -CF3, halo.
6. The compound of Claim 1 wherein R5 is the group represented by chloro, bromo, COOH, or CF3.
7. A compound of formula (I) selected from the group consisting of: 3-oxo-3H-benzo [d]isoxazole-2-carboxy] lie acid ethylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid butylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid hexylamide, 3-oxo-3H-benzo [J]isoxazole-2-carboxy] lie acid (5-methyl-hexyl)amide, 3-oxo-3H-benzo [<i]isoxazole-2-carboxy lie acid (5 -methyl -hexyl)amide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy lie acid octylamide, 3-oxo-3H-benzo [</]isoxazole-2-carboxy] lie acid cyclohexylmethyl-amide, 3-oxo-3H-benzo [djisoxazole-2-carboxy] lie acid 4-nitro-phenyl ester, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid cyclohexylmethyl-amide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid 2-methyl-benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid 3-methyl-benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid 4-methyl-benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid 2-trifluorometlιyl-benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy] lie acid 2-fluoro-benzylamide, 3-oxo-3H-benzo [rf]isoxazole-2-carboxy] lie acid 4-fluoro-benzylamide, 3-oxo-3H-benzo [<i]isoxazole-2-carboxy] lie acid 2-ethyl-benzylamide, 3-oxo-3H-benzo [ ]isoxazole-2-carboxy lie acid 3-ethyl-benzylamide, 3-oxo-3H-benzo [ύQisoxazole-2-carboxy lie acid 4-te7't-butyl-benzylamide, 3-oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide, 3-oxo-3H-benzo[(f]isoxazole-2-carboxylic acid 3-methoxy-benzylamide, 3-oxo-3H-benzo[ ]isoxazole-2-carboxylic acid 4-methoxy-benzylamide, 3-oxo-3H-benzo[( |isoxazole-2-carboxylic acid 2-ethoxy-benzylamide, 3-oxo-3H-benzo[d]isoxazole-2-carboxylic acid 3-ethoxy-benzylamide, 3-oxo-3H-benzo[<i]isoxazole-2-carboxylic acid 4-ethoxy-benzylamide, 3-oxo-3H-benzo[ti]isoxazole-2-carboxylic acid phenethyl-amide, and a pharmaceutically acceptable salt, solvate, racemate, enantiomer or diastereomeric mixture thereof.
8. A 3-oxo-3H-benzo[d]isoxazole carboxamide compound represented by the formulae (CI), (C2), (C3), (C4), and (C5):
Figure imgf000042_0001
(C2),
Figure imgf000042_0002
(C4),
Figure imgf000043_0001
C5, or a pharmaceutically acceptable salt, or solvate, thereof.
9. A pharmaceutical formulation comprising a 3-oxo-3H-benzo[< ]isoxazole carboxamide compound of formula I together with a pharmaceutically acceptable carrier or diluent.
10. A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of 3-oxo-3H-benzo[J]isoxazole carboxamide compound of fomiula I.
11. A method of treating a mammal to alleviate the pathological effects of low HDL associated with elevated hepatic lipase and/or endothelial lipase activity wherein the method comprises administering to said mammal a therapeutically effective amount of a 3~oxo-3.H-benzo[d]isoxazole carboxamide compound of formula I.
12. A method of treating a mammal afflicted with low LDL comprising administering to said mammal a therapeutically effective amount of a compound of formula I.
13. Use of a pharmaceutical composition comprising a therapeutically effective amount of a hepatic lipase and/or endothelial lipase inhibitor compound according to Claim 1 and mixtures thereof for the manufacture of a medicament for the treatment of disease mediated by hepatic lipase and/or endothelial lipase activity.
14. Use of a 3-oxo-3H-benzo[ ]isoxazole carboxamide compound of formula I for the manufacture of a medicament for the treatment or prevention of hepatic lipase and/or endothelial lipase mediated disease comprising administering a therapeutically effective amount of said compound of formula (I), or a pharmaceutically acceptable salt, or solvate to a patient in need thereof.
PCT/US2004/006095 2003-04-01 2004-03-25 Phospholipase inhibitors WO2004094393A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP04723449A EP1613608A1 (en) 2003-04-01 2004-03-25 Phospholipase inhibitors
US10/544,908 US7217727B2 (en) 2003-04-01 2004-03-25 Phospholipase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45983303P 2003-04-01 2003-04-01
US60/459,833 2003-04-01

Publications (1)

Publication Number Publication Date
WO2004094393A1 true WO2004094393A1 (en) 2004-11-04

Family

ID=33310712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/006095 WO2004094393A1 (en) 2003-04-01 2004-03-25 Phospholipase inhibitors

Country Status (3)

Country Link
US (1) US7217727B2 (en)
EP (1) EP1613608A1 (en)
WO (1) WO2004094393A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111321A1 (en) * 2005-04-20 2006-10-26 Sanofi-Aventis Azole derivatives in the form of lipase and phospholipase inhibitors
WO2006131231A1 (en) 2005-06-09 2006-12-14 Sanofi-Aventis Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
WO2006131233A1 (en) 2005-06-09 2006-12-14 Sanofi-Aventis Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
WO2007110216A1 (en) * 2006-03-28 2007-10-04 Sanofi-Aventis Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
US7355055B2 (en) 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
WO2008122352A1 (en) 2007-04-05 2008-10-16 Sanofi-Aventis Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
WO2008122357A1 (en) * 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles as inhibitors of lipases and phospholipases
WO2010044441A1 (en) 2008-10-17 2010-04-22 塩野義製薬株式会社 Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
US7709509B2 (en) 2004-04-01 2010-05-04 Sanofi-Aventis Deutschland Gmbh Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists
WO2011074560A1 (en) 2009-12-15 2011-06-23 塩野義製薬株式会社 Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013048942A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013049096A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048982A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048930A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013151877A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
WO2013151923A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase
WO2014011513A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
WO2014011461A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Amide or urea substituted benzothiazole derivatives as inhibitors of endothelial lipase
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
CN104136443A (en) * 2011-12-20 2014-11-05 赛诺菲 Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals
WO2015105749A1 (en) 2014-01-07 2015-07-16 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
EP2915882A1 (en) * 2012-11-05 2015-09-09 Shionogi & Co., Ltd. Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
US9169240B2 (en) 2012-09-11 2015-10-27 Bristol-Myers Squibb Company Ketone linked benzothiazole inhibitors of endothelial lipase
WO2017214005A1 (en) 2016-06-06 2017-12-14 Bristol-Myers Squibb Company 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2257750A1 (en) * 1972-11-24 1974-05-30 Sankyo Co 2-cyclic amino carbonyl-4-isoxazoline-3-ones - as analgesic antiinflammatory,anti-tussive and anti-hypertensive agents
EP0684242A1 (en) * 1993-12-27 1995-11-29 Japan Tobacco Inc. Isoxazolidinedione derivative and use thereof
EP0897903A2 (en) * 1997-08-11 1999-02-24 Eli Lilly And Company Ketone-derivatives of indene, dihydronaphthalene or naphthalene compounds for the treatment of hyperlipidemia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2257750A1 (en) * 1972-11-24 1974-05-30 Sankyo Co 2-cyclic amino carbonyl-4-isoxazoline-3-ones - as analgesic antiinflammatory,anti-tussive and anti-hypertensive agents
EP0684242A1 (en) * 1993-12-27 1995-11-29 Japan Tobacco Inc. Isoxazolidinedione derivative and use thereof
EP0897903A2 (en) * 1997-08-11 1999-02-24 Eli Lilly And Company Ketone-derivatives of indene, dihydronaphthalene or naphthalene compounds for the treatment of hyperlipidemia

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709509B2 (en) 2004-04-01 2010-05-04 Sanofi-Aventis Deutschland Gmbh Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists
WO2006111321A1 (en) * 2005-04-20 2006-10-26 Sanofi-Aventis Azole derivatives in the form of lipase and phospholipase inhibitors
US8921404B2 (en) 2005-04-20 2014-12-30 Sanofi Azole derivatives in the form of lipase and phospholipase inhibitors
US7709513B2 (en) 2005-06-09 2010-05-04 Sanofi-Aventis Benzooxazol-2-one derivatives as lipase and phospholipase inhibitors
WO2006131231A1 (en) 2005-06-09 2006-12-14 Sanofi-Aventis Azolopyridine-2-on derivatives as lipase and phospholipase inhibitors
WO2006131233A1 (en) 2005-06-09 2006-12-14 Sanofi-Aventis Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
US7846943B2 (en) 2005-06-09 2010-12-07 Sanofi-Aventis Azolopyridin-2-one derivatives as lipase and phospholipase inhibitors
US7355055B2 (en) 2005-09-08 2008-04-08 Reliance Life Sciences Pvt. Ltd. Compounds for treatment of lipase-mediated diseases
WO2007110216A1 (en) * 2006-03-28 2007-10-04 Sanofi-Aventis Azolopyridin-3-one derivatives as inhibitors of endothelial lipase
DE102006014688A1 (en) * 2006-03-28 2007-10-04 Sanofi-Aventis New bicyclic pyrazolone or isoxazolone derivatives useful as endothelial lipase inhibitors, e.g. for treating disorders of fat metabolism or glucose utilization
US8148395B2 (en) 2006-03-28 2012-04-03 Sanofi-Aventis Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8735437B2 (en) 2007-04-05 2014-05-27 Sanofi Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
WO2008122357A1 (en) * 2007-04-05 2008-10-16 Sanofi-Aventis 5-oxo-isoxazoles as inhibitors of lipases and phospholipases
WO2008122352A1 (en) 2007-04-05 2008-10-16 Sanofi-Aventis Imidazolidine carboxamide derivatives as lipase and phospholipase inhibitors
US9029400B2 (en) 2007-04-05 2015-05-12 Sanofi 5-oxoisoxazoles as inhibitors of lipases and phospholipases
JPWO2010044441A1 (en) * 2008-10-17 2012-03-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
WO2010044441A1 (en) 2008-10-17 2010-04-22 塩野義製薬株式会社 Acetic acid amide derivative having inhibitory activity on vascular endothelial lipase
JP5605844B2 (en) * 2008-10-17 2014-10-15 塩野義製薬株式会社 Acetic acid amide derivatives having vascular endothelial lipase inhibitory activity
US8957219B2 (en) 2008-10-17 2015-02-17 Shionogi & Co., Ltd. Acetic acid amide derivative having inhibitory activity on endothelial lipase
US8754113B2 (en) 2009-12-15 2014-06-17 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011074560A1 (en) 2009-12-15 2011-06-23 塩野義製薬株式会社 Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2013049096A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9120794B2 (en) 2011-09-27 2015-09-01 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048982A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8952180B2 (en) 2011-09-27 2015-02-10 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9249096B2 (en) 2011-09-27 2016-02-02 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
WO2013049104A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
US8933235B2 (en) 2011-09-30 2015-01-13 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
US8946430B2 (en) 2011-09-30 2015-02-03 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013048942A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
WO2013048930A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN104136443B (en) * 2011-12-20 2017-01-18 赛诺菲 Isothiazole pyridine-2-carboxamide and they purposes as medicine
CN104136443A (en) * 2011-12-20 2014-11-05 赛诺菲 Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals
US9260454B2 (en) 2011-12-20 2016-02-16 Sanofi Isothiazolopyridine-2-carboxamides and their use as pharmaceuticals
WO2013151923A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinone carboxamides as inhibitors of endothelial lipase
WO2013151877A1 (en) 2012-04-03 2013-10-10 Bristol-Myers Squibb Company Pyrimidinedione carboxamide inhibitors of endothelial lipase
US9394260B2 (en) 2012-04-03 2016-07-19 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
US9199946B2 (en) 2012-04-03 2015-12-01 Bristol-Myers Squibb Company Pyrimidinone carboxamide inhibitors of endothelial lipase
US8680090B2 (en) 2012-07-09 2014-03-25 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
US9139578B2 (en) 2012-07-09 2015-09-22 Bristol-Myers Squibb Company Amide or urea containing benzothiazole inhibitors of endothelial lipase
WO2014011513A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Sulfonyl containing benzothiazole inhibitors of endothelial lipase
WO2014011461A1 (en) 2012-07-09 2014-01-16 Bristol-Myers Squibb Company Amide or urea substituted benzothiazole derivatives as inhibitors of endothelial lipase
US8987314B2 (en) 2012-07-19 2015-03-24 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2014015088A1 (en) 2012-07-19 2014-01-23 Bristol-Myers Squibb Company Amide, urea or sulfone amide linked benzothiazole inhibitors of endothelial lipase
US9169240B2 (en) 2012-09-11 2015-10-27 Bristol-Myers Squibb Company Ketone linked benzothiazole inhibitors of endothelial lipase
EP2915882A1 (en) * 2012-11-05 2015-09-09 Shionogi & Co., Ltd. Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
EP2915882A4 (en) * 2012-11-05 2016-04-27 Shionogi & Co Method for evaluating drug activity of medicine having therapeutic or preventive effect on disease to which el activity relates, and method for screening for el activity inhibitory substance
US9695462B2 (en) 2012-11-05 2017-07-04 Shionogi & Co., Ltd. Method for evaluation of drug efficacy of a medicine having a therapeutic or preventive effect against a disease related to EL activity and a method for screening an inhibitor of EL activity
WO2015105749A1 (en) 2014-01-07 2015-07-16 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
US10173991B2 (en) 2014-01-07 2019-01-08 Bristol-Myers Squibb Company Sulfone amide linked benzothiazole inhibitors of endothelial lipase
WO2017214005A1 (en) 2016-06-06 2017-12-14 Bristol-Myers Squibb Company 2-(benzothiazol-2-yl)-2-cyano-acetamide derivatives and their use as endothelial lipase inhibitors

Also Published As

Publication number Publication date
US7217727B2 (en) 2007-05-15
EP1613608A1 (en) 2006-01-11
US20060116409A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
EP1613608A1 (en) Phospholipase inhibitors
US11084802B2 (en) THRβ receptor agonist compound and preparation method and use thereof
EP1615900A1 (en) Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
EP1610779B1 (en) 3-oxo-1,3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors
EP1732933B1 (en) Compounds for treating dyslipidemia
RU2039042C1 (en) Process for preparing 3-substituted-2-oxoindoles
JP2656189B2 (en) Benzoisothiazole and benzisoxazole-3-carboxamides, their preparation and antipsychotics comprising them
BR112020000180A2 (en) fxr receptor agonist
PT2401269E (en) Indole derivatives as crth2 receptor antagonists
JP2006516290A (en) 17-carbamoyloxycortisol derivatives as selective glucocorticoid receptor modulators
EP1761521A1 (en) Compounds and methods for treating dyslipidemia
CA2554610A1 (en) Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors
EP3144303B1 (en) 6-substituted phenoxychroman carboxylic acid derivatives
WO2020156241A1 (en) Aromatic ring or heteroaromatic ring compounds, preparation method therefor and medical use thereof
JP2020519651A (en) LXR modulator containing amine or (thio)amide
JP2020502129A (en) 3-oxo-1,4-diazepinyl compounds as NRF2 activators
EP0934319A1 (en) 1H-PYRIDO[3,4-b]INDOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND APPLICATION THEREOF IN THERAPEUTICS
KR20160020616A (en) Compounds for treatment of inflammatory diseases
CA2140953A1 (en) Polyhydronorharman synthase inhibitors
US5830902A (en) Quinuclidine derivative having tricyclic hetero condensed ring
JP2022521895A (en) Substituted bicyclic compounds as farnesoid X receptor modulators
CN117285504A (en) Amino phenylacetamide derivative and preparation method and application thereof
BR122023027289A2 (en) THRbeta RECEPTOR AGONIST COMPOUND, ITS USES, AND PHARMACEUTICAL COMPOSITION
WO2011083278A1 (en) Novel benzoic pyrrolopyridine derivatives
JPH0977744A (en) Indole derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006116409

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10544908

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004723449

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004723449

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10544908

Country of ref document: US